Sentences with phrase «promising efficacy and safety»

AST - VAC1 (antigen - presenting autologous dendritic cells) is an autologous cancer immunotherapy with promising efficacy and safety data from a Phase 2 study in Acute Myeloid Leukemia (AML).

Not exact matches

«This type of combination therapy is promising but more work is needed to determine its safety and efficacy,» Grønbæk said.

Two new phase III clinical trials investigating the efficacy and safety of bitopertin, a glycine uptake inhibitor considered to be a promising new add - on therapy for treating negative symptoms in schizophrenia, failed to show a benefit of the drug over placebo.

Promising outcomes of preliminary studies in patients in Southeast Asia and parts of Western and Central Africa led the World Health Organization to make the recommendation, but safety and efficacy have not yet been proven in large - scale clinical trials.

Since there is no vaccine or specific approved treatment for Ebola virus disease (EVD), there is a «moral obligation» to collect and share all data generated, to understand the safety and efficacy of any intervention, and to evaluate promising interventions to inform future research, says Dr. Eleanor Fish, the senior author and senior scientist in the Toronto General Hospital Research Institute (TGHRI).

PD01A: Promising Animal Efficacy; Initial Human Safety and Hints of Disease Modification At the time of our last post on α - synuclein vaccines, AFFiRiS had published several papers about the AFFITOME immnotherapy discovery platform [8 - 11] and had even begun their first Phase I trial of PD01A, but had kept nearly silent on many of the most elementary aspects of the vaccine.

Whilst initial findings are promising, the long - term efficacy, safety, and whether these metabolic improvements can be maintained during weight - stabilization, remain unknown.

There's still a lot more to learn about their safety and efficacy, but so far it looks promising.

The patents considered in «elevated Promise» cases arguably have fairly clear technical deficiencies — for example, claiming a group of compounds where admittedly many of the compounds did not even have minimal activity [1]; asserting a new compound is an effective, less irritating eye drug, when admittedly eye drugs must have chronic safety tests and no tests had been done [2]; asserting a compound has clinical safety / efficacy, when in fact only preliminary tests had been conducted [3].